B.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...
B.Riley Financial Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DOJoPAWP.js ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...
Business Insider25d
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $7.00.
Business Insider25d
B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $236.00. The company ...